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ABSTRACT
Purpose: To study were to reproduce an alveolar bone defect model in Wistar rats to be used for testing the efficacy of stem cell
therapies. Additionally, we also aimed to determine the osteogenesis process of this osseous defect in the 1 month period post-surgery.
Methods: The animals were randomly divided into two groups of 7 animals each. A gingivobuccal incision was made, and a bone defect
of 28 mm2 of area was performed in the alveolar region. Animals were killed at 2 weeks after surgery (n=7) and 4 weeks after surgery
(n=7). Results: The average area of the alveolar defect at time point of 2 weeks was 22.27 ± 1.31 mm2 and the average area of alveolar
defect at time point of 4 weeks was 9.03 ± 1.17 mm2. The average amount of bone formation at time point of 2 weeks was 5.73 ± 1.31
mm2 and the average amount of bone formation at time point of 4 weeks was 19 ± 1.17 mm2. Statistically significant differences between
the amount of bone formation at 2 weeks and 4 weeks after surgery were seen (p=0.003).Conclusion: The highest rate of ossification
occurred mostly from 2 to 4 weeks after surgery. This observation suggests that 4 weeks after the bone defect creation should be a
satisfactory timing to assess the potential of bone inductive stem cells to accelerate bone regeneration in Wistar rats.
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RESUMO
Objetivo: Reproduzir um novo modelo de defeito ósseo alveolar em ratos Wistar que será utilizado para terapia genética e estudos com
células tronco. Adicionalmente, outro objetivo do presente estudo foi determinar o pico de regeneração óssea do defeito criado na região
alveolar do modelo experimental. Métodos: Os animais foram aleatoriamente divididos em dois grupos de sete animais. Através de uma
incisão gengivobucal foi criado um defeito ósseo medindo 28 mm2 de área na região alveolar dos ratos. Os ratos foram sacrificados após
duas semanas (n=7) e quatro semanas (n=7) da cirurgia. Resultados: A área média do defeito alveolar após duas semanas de cirurgia foi
de 22.27 ± 1.31 mm2 e a área média do defeito alveolar após quatro semanas de cirurgia foi de 9.03 ± 1.17 mm2. A taxa de formação óssea
foi de 5.73 ± 1.31 mm2 após duas semanas de cirurgia e de 19 ± 1.17 mm2 após quatro semanas de cirurgia. Foi observada diferença
estatisticamente significante na taxa de formação óssea entre o grupo dos animais sacrificados com duas e quatro semanas (p=0.003).
Conclusão: Este estudo demonstrou que a maior taxa de regeneração óssea ocorreu no período entre duas e quatro semanas após a
cirurgia de criação do defeito ósseo alveolar, portanto esta observação sugere que o período de tempo de quatro semanas será suficiente
para avaliar a capacidade de células tronco em regenerar osso em ratos Wistar com defeito ósseo alveolar.
Descritores: Perda Óssea Alveolar. Terapia Celular. Ratos.
1Research performed at Department of Genetics and Evolution Biology, Institute of Biosciences, University of São Paulo (USP), Brazil.
Introduction
Cleft lip and palate (CLP) represent one of the most
common congenital human malformations, corresponding to
nearly 1/3 of all birth defects. They are very heterogeneous and
etiologically complex. The phenotype can vary from simple lip scar
or a cleft lip to a complex craniofacial pattern involving the palate,
maxilla, zygoma, orbit and cranium. The incidence of the different
forms vary: cleft lip with or without cleft palate (CLP) is the most
frequent (~1:1000 live births) while craniofacial clefts are quite
rare, with an estimate incidence of 1.43 to 4.84 per 100 000 live
births1-3.
Surgical correction of CLP cleft can be challenging.
Strategies for closing the bone defect include  autologous  bone
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grafts and soft tissue repair with local flaps4. An adequate bone
stock in the cleft region is required to establish continuity of the
craniofacial skeleton. In addition, satisfactory bone stock in the
cleft region is required to facilitate tooth eruption and the closure
of oronasal fistulas5-10. Older patients with  cleft lip and/or cleft
palate may experience slow wound healing, bone graft absorption
or recurrent fistulas, resulting in failed tooth eruption11. Early
treatment may avoid an unsatisfactory outcome.
An alternative promising technique to enhance bone
regeneration in patients with CLP involves the use of tissue-
engineered bone, which involves stem cells of various sources with
osteogenic potential placed within a biocompatible scaffold7,12,13.
An appropriate animal model is essential for testing
tissue-engineered bone and new strategies for healing bone
defects12,14-16. Alveolar maxillary bone defects have been described
in primate, ovine and canine models17-20, however, the use of large
animals is expensive and requires a specific setting.
Rodent models have been used in the majority of studies,
investigating new bone-inductive agents13-16,21,22. Mehrara et al.15
created a rat model of gingivoperiosteoplasty in which a bone
defect in the palatal bone was produced15. However, the lack of
soft tissue coverage of rat palatal bone may be a limitation of this
model with regard to the development of three dimensional
biocompatible scaffolds seeded with cells for bone regeneration.
Nguyen et al.23 recently established a critical-sized alveolar defect
in rats and determined by means of micro-computed tomography
and histology the ratio of ossification at 4, 8 and 12 weeks after
surgery. They did not observe statistically significant difference in
bone formation among 4, 8 and 12 weeks, suggesting that 4 weeks
would be a plateau of bone formation.
The purposes of the present study were to reproduce an
alveolar bone defect model in Wistar rats to be used for testing
the efficacy of stem cell therapies as well as to determine the rate
of bone formation of this osseous defect within the first month
post-surgery.
Methods
All experiments were performed in accordance with the
guidelines set by the Standing Committee on Animal Research of
the Institute of Bioscience, University of São Paulo. Adult male,
4-months-old, Wistar-rats, weighing 350g to 500g, were housed
individually in a temperature-, light-,and humidity- controlled
environment. Animals were fed a standard diet preoperatively.
Postoperatively, animals were fed a soft diet for 1 week, after which
the normal diet was re-established.
Surgical procedure
Animals were anesthetized with an intraperitoneal
injection (0.3 mL/100 g body weight) of ketamine hydrochloride
(5%) combined with xylazine (2%).  Rats were placed in a lateral
position for the surgical procedure. Lidocaine with adrenaline, (0.3
mL) was used for anesthesia of the oral mucosa. A 1.5-cm incision
was made in the transitional zone of dry to wet oral mucosa. A
tongue traction maneuver was performed to keep the airway open
during the surgical procedure.  The underlying muscle and
maxillary periosteum were elevated. The maxilla and zygomatic bone
were completely undermined. A fabricated methyl methacrylate
rectangular mold was used to produce a standardized bone defect
of 28 mm2 of area (7 mm anteroposterior, 4 mm mediolateral and,
2 mm deep). A caliper was used to measure the bone defect. A
high-speed burr with constant irrigation was used to create the
bone defect. One rat aspirated   water during surgery and died. This
animal was replaced. Otherwise, all 14 rats tolerated the surgical
procedure well.  They were fed a standard soft diet for 1 week
after surgery and seemed to eat without problem; average weight
loss at 4 weeks was 25 g, corresponding to a 6% to 7 % loss of
body weight. Animals were killed at 2 and 4 weeks (n=7 per time
point) by carbon dioxide narcosis. The size of bone defect as
well as measurement of bone formation at each time point were
performed and compared (Figures 1 and 2).
FIGURE 1 - Wistar rats were placed in a lateral position. A 1.5-cm
incision was made in the gingivobuccal sulcus. The muscles of the face
were released, and the periosteum was retracted. A methyl methacrylate
mold was placed into the appropriate position, and a bone defect was
created with a high-speed burr. The tongue was pulled out to avoid water
aspiration and to facilitate breathing
FIGURE 2 - Illustration of the bone defect compromising the maxillary
and alveolar regions
Histologic preparation
Samples of the alveolar bone defect were prepared for
histologic analysis. The studied tissue samples were fixed in 10%
formalin for 24 hours, decalcified in 5 % formic acid for 48 hours,
and paraffin-embedded. Sections measuring 5 µm were stained with
hematoxylin and eosin and examined under a light microscope.
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Radiographic analysis
Rats craniofacial skeleton were imaged immediately after
surgery and postoperatively at 2 weeks (n=7) and 4 weeks (n=7)
by computerized tomography. Scans were reconstructed as tree-
dimensional isosurfaces using InVesalius biomedical software
(DT3D-CTI-Brazil). Each tree-dimensional imaging was evaluated
at a critical threshold toll, with the densest intensity interpreted
as bone. The area of the bone defect was measured on a tree-
dimensional images using Magics 13.0 (Materialise-Belgic,
software CAD) at O, 2 and 4 weeks.
Measurement of bone formation
The amount of bone formation was measured by
calculating the difference between the initial size of bone defect
from the size of the bone defect at 4 weeks and 2 weeks after
surgery.
Statistical analysis
The amount of bone formation at 2 weeks and 4 weeks
after surgery were compared using a Mann-Whitney test. All data
were expressed as mean± SEM. A value of p<0.05 was considered
to be statistically significant.
Results
The average area of the alveolar defect at 2 weeks after
surgery was 22.27 ± 1.31 mm2 and the average area of alveolar
defect at 4 weeks after surgery was 9.03 ± 1.17 mm2. The average
amount of bone formation at time point of 2 weeks was 5.73 ± 1.31
mm2 and the average amount of bone formation at time point of
4 weeks was 19 ± 1.17 mm2. Statistically significant differences
between the amount of bone formation at 2 weeks and 4 weeks
after surgery was seen (p=0.003). Our study showed that the
highest rate of ossification occurred mostly from 2 to 4 weeks,
being more than two times higher at 4weeks period in comparison
of 2 weeks period (Figure 3).
FIGURE 3 - Computerized tomography imaging showing the initial size
of bone defect with 28 mm2 of area (above) and at 2 weeks and 4 weeks
after surgery (below, left and below, right). Note that the bone defect is
demonstrated with arrows
Histologically, intense osteoblast activities with
polymorphonuclear cells as well as woven bone layer was seen
(Figures 4 and 5).
 
FIGURE 4 - Photomicrographs obtained for histologic evaluation (100X
magnification). Sagittal sections of rats maxillary region, showing intense
osteblastic activity (large arrow), woven bone within the alveolar gap (small
arrow)
FIGURE 5 - Photomicrographs obtained for histologic evaluation (100X
magnification). Sagittal sections of rats maxillary region, fibroblast
(large arrow) and matrix collagen fibers (small arrow) are also seen in the
alveolar bone defect
Discussion
Currently, CLP teams are focused to decrease the number
of operations of their children during the process of rehabilitation.
Attempts of early bone grafting with rib has brought several
complications as well as high morbidity of donor sites23.
Gingivoperiosteoplasty (GPP) was an alternative
technique described in 1965 that aimed to regenerate bone on the
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further cell therapy testing. Results of this study suggests that
4 weeks after the bone defect creation should be a satisfactory
timing to assess the potential of bone inductive agents, including
stem cells to accelerate bone regeneration and answer the queries
previously raised. Our results suggested that most of the
osteogenesis phenomenon occurred from 0 to 4 weeks in this
animal model. In summary, this model will allow studies with
tissue-engineered bone associated with stem cells in order to
evaluate the effectiveness of strategies to speed up the healing
process of CLP alveolar defects, leading to early rehabilitation of
these children.
Conclusion
Our study showed that the highest rate of ossification
occurred mostly from 2 to 4 weeks after the alveolar bone defect
creation. This observation together with the data on the literature
suggests that 4 weeks after the bone defect creation should be a
satisfactory timing to assess the potential of bone inductive stem
cells to accelerate bone regeneration in Wistar rats.
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alveolar defect, without the potential complication of having a
donor site at early age24. However, studies have described variable
rates of success of bone regeneration on the alveolar defects and
long term complications on facial growth25,26.
Tissue engineering studies have identified alternative
methods that may allow early rehabilitation and decreased average
number of operations until adult age. Bone morphegenic protein
(BMP-2) was used to reconstruct cranial defects27. Alonso et al.29
have demonstrated in a clinical study that the reossification
occurred in different distribution pattern and more slowly in the
group of BMP in comparison with the group of iliac crest bone
graft, that remains as gold standard therapy for alveolar cleft
repair28. The potential of bone formation after placement of
BMP was also showed in animal models with cranial defects29.
Interestingly, BMP did not cause immunologic reaction after its
use in a rat model. Stem cells with osteogenic potential has been
another alternative, that may be used in further clinical trials to
promote early rehabilitation of children with cleft lip and palate.
Bone marrow stem cells seeded onto a resorbable sponge with
satisfactory bone healing outcomes has shown several advantages
regarding to donor site morbidity7. Ideally, patients would be
benefited with autologous sources of stem cells, however it may
not be promptly available. A novel source of osteogenic stem cell
were isolated from the lip muscle of children born with CLP. Small
fragments of lip muscle are commonly discarded after primary
surgery of cleft lip repair at 3 months of age30. Bone inductive stem
cells could be included in the alveolar pocket of patients with
CLP at the time of palate repair, promoting bony growth and
consequently early rehabilitation. Alternatively, a stem cells bank
would lead widespread use for early rehabilitation of the growing
population of cleft children. However, several issues need to be
addressed before its use in clinical trials, such as; 1- amount of
stem cells needed to regenerate sufficient bone in the alveolar gap.
2- The possibility of using heterologous sources of stem cells from
stem cells bank. 3- Quality and amount of bone formed in the
alveolar gap. For this reason an animal model, that allows some
answers prior to clinical trials is primordial. In the present study,
we reproduced an osseous defect in the maxillary alveolar region
of Wistar rats. The present report confirms that after one month
post-surgery the original defect of 28 mm2 was still not healed. We
also observed that the highest rate of ossification occurred mostly
from 2 to 4 weeks. Histologically, osteoblast activities and
polymorphonuclear cells as well as woven bone layers are seen,
suggesting intense osteogenesis phenomenon, however, this
process does not seem enough to totally regenerate the bone
defect. Considering that a plateau of bone formation starting at
4 weeks after surgery was previously demonstrated31, we suggest
that evaluation at 4 weeks after the bone defect creation should
be a satisfactory timing to assess the potential of bone inductive
stem cells to accelerate bone regeneration in Wistar rats.
The model presented herein is an alveolar osseous defect,
that is, on the other hand, reproducible and feasible, that simulates
the tridimensional osseous defect in cleft lip/palate patients.
Traditionally, bone calvarial defects are being used to study bone
inductive agents, however satisfactory results achieved in the
cranial bone would not be replicable to alveolar and maxillary
bone, because of the role of dura mater and pericranium on the
bone formation. This is a preliminary report constructed for
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